421 related articles for article (PubMed ID: 11101361)
1. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE
J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361
[TBL] [Abstract][Full Text] [Related]
2. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
Blair JB; Marona-Lewicka D; Kanthasamy A; Lucaites VL; Nelson DL; Nichols DE
J Med Chem; 1999 Mar; 42(6):1106-11. PubMed ID: 10090793
[TBL] [Abstract][Full Text] [Related]
3. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
[TBL] [Abstract][Full Text] [Related]
4. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
5. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
[TBL] [Abstract][Full Text] [Related]
6. Abuse liability profile of three substituted tryptamines.
Gatch MB; Forster MJ; Janowsky A; Eshleman AJ
J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
Chambers JJ; Parrish JC; Jensen NH; Kurrasch-Orbaugh DM; Marona-Lewicka D; Nichols DE
J Med Chem; 2003 Jul; 46(16):3526-35. PubMed ID: 12877591
[TBL] [Abstract][Full Text] [Related]
8. Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain.
Gerasimov M; Marona-Lewicka D; Kurrasch-Orbaugh DM; Qandil AM; Nichols DE
J Med Chem; 1999 Oct; 42(20):4257-63. PubMed ID: 10514296
[TBL] [Abstract][Full Text] [Related]
9. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.
Smith RL; Canton H; Barrett RJ; Sanders-Bush E
Pharmacol Biochem Behav; 1998 Nov; 61(3):323-30. PubMed ID: 9768567
[TBL] [Abstract][Full Text] [Related]
10. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
Nichols DE; Frescas S; Marona-Lewicka D; Kurrasch-Orbaugh DM
J Med Chem; 2002 Sep; 45(19):4344-9. PubMed ID: 12213075
[TBL] [Abstract][Full Text] [Related]
11. 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.
Glennon RA; Lee M; Rangisetty JB; Dukat M; Roth BL; Savage JE; McBride A; Rauser L; Hufeisen S; Lee DK
J Med Chem; 2000 Mar; 43(5):1011-8. PubMed ID: 10715164
[TBL] [Abstract][Full Text] [Related]
12. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.
Carbonaro TM; Eshleman AJ; Forster MJ; Cheng K; Rice KC; Gatch MB
Psychopharmacology (Berl); 2015 Jan; 232(1):275-84. PubMed ID: 24985890
[TBL] [Abstract][Full Text] [Related]
13. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
Halberstadt AL; Koedood L; Powell SB; Geyer MA
J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
[TBL] [Abstract][Full Text] [Related]
14. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists.
Chambers JJ; Kurrasch-Orbaugh DM; Parker MA; Nichols DE
J Med Chem; 2001 Mar; 44(6):1003-10. PubMed ID: 11300881
[TBL] [Abstract][Full Text] [Related]
15. Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist.
Miranda F; Orozco G; Velázquez-Martínez DN
Behav Pharmacol; 2002 Jul; 13(4):303-11. PubMed ID: 12218511
[TBL] [Abstract][Full Text] [Related]
16. Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes.
Whiteside MS; Kurrasch-Orbaugh D; Marona-Lewicka D; Nichols DE; Monte A
Bioorg Med Chem; 2002 Oct; 10(10):3301-6. PubMed ID: 12150876
[TBL] [Abstract][Full Text] [Related]
17. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
18. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
Nichols DE; Frescas S; Marona-Lewicka D; Huang X; Roth BL; Gudelsky GA; Nash JF
J Med Chem; 1994 Dec; 37(25):4346-51. PubMed ID: 7996545
[TBL] [Abstract][Full Text] [Related]
19. 5-Hydroxytryptamine(1A) receptor-stimulated [(35)S]GTPgammaS binding in rat brain: absence of regional differences in coupling efficiency.
Meller E; Li H; Carr KD; Hiller JM
J Pharmacol Exp Ther; 2000 Feb; 292(2):684-91. PubMed ID: 10640306
[TBL] [Abstract][Full Text] [Related]
20. 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.
McLean TH; Parrish JC; Braden MR; Marona-Lewicka D; Gallardo-Godoy A; Nichols DE
J Med Chem; 2006 Sep; 49(19):5794-803. PubMed ID: 16970404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
